EA201890497A2 - METHOD OF TREATMENT OF LABEL AND PAROXISMAL HYPERTENSION - Google Patents

METHOD OF TREATMENT OF LABEL AND PAROXISMAL HYPERTENSION

Info

Publication number
EA201890497A2
EA201890497A2 EA201890497A EA201890497A EA201890497A2 EA 201890497 A2 EA201890497 A2 EA 201890497A2 EA 201890497 A EA201890497 A EA 201890497A EA 201890497 A EA201890497 A EA 201890497A EA 201890497 A2 EA201890497 A2 EA 201890497A2
Authority
EA
Eurasian Patent Office
Prior art keywords
hypertension
paroxismal
label
treatment
present
Prior art date
Application number
EA201890497A
Other languages
Russian (ru)
Other versions
EA201890497A3 (en
EA034975B1 (en
Inventor
Владимир Александрович Горшков-Кантакузен
Original Assignee
Владимир Александрович Горшков-Кантакузен
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Владимир Александрович Горшков-Кантакузен filed Critical Владимир Александрович Горшков-Кантакузен
Priority to EA201890497A priority Critical patent/EA034975B1/en
Publication of EA201890497A2 publication Critical patent/EA201890497A2/en
Publication of EA201890497A3 publication Critical patent/EA201890497A3/en
Publication of EA034975B1 publication Critical patent/EA034975B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к области медицины, конкретно к способу медикаментозного лечения лабильной и параксизмальной форм гипертензии. Способ включает введение субъекту, который в этом нуждается, терапевтически эффективного количества сартана и α-блокатора. Настоящее изобретение позволяет снизить лабильность артериального давления, а также купировать сопутствующие симптомы.The present invention relates to the field of medicine, specifically to the method of medical treatment of labile and paraxysmal forms of hypertension. The method includes administering to a subject in need thereof a therapeutically effective amount of a sartan and an α-blocker. The present invention allows to reduce the lability of blood pressure, as well as arrest the associated symptoms.

EA201890497A 2018-03-13 2018-03-13 Method of treating labile and paroxysmal hypertension EA034975B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA201890497A EA034975B1 (en) 2018-03-13 2018-03-13 Method of treating labile and paroxysmal hypertension

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA201890497A EA034975B1 (en) 2018-03-13 2018-03-13 Method of treating labile and paroxysmal hypertension

Publications (3)

Publication Number Publication Date
EA201890497A2 true EA201890497A2 (en) 2018-09-28
EA201890497A3 EA201890497A3 (en) 2018-12-28
EA034975B1 EA034975B1 (en) 2020-04-13

Family

ID=63667385

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890497A EA034975B1 (en) 2018-03-13 2018-03-13 Method of treating labile and paroxysmal hypertension

Country Status (1)

Country Link
EA (1) EA034975B1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0400475A3 (en) * 2000-04-12 2006-02-28 Novartis Ag Pharmaceutical compositions containing combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups and use thereof
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
US20050187262A1 (en) * 2004-01-12 2005-08-25 Grogan Donna R. Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use
KR101708538B1 (en) * 2011-08-26 2017-02-20 욱크하르트 리미티드 Methods for treating cardiovascular disorders

Also Published As

Publication number Publication date
EA201890497A3 (en) 2018-12-28
EA034975B1 (en) 2020-04-13

Similar Documents

Publication Publication Date Title
EA202090955A1 (en) METHODS OF USING EHMT2 INHIBITORS IN TREATMENT OR PREVENTION OF BLOOD DISORDERS
EA201690212A1 (en) METHODS OF TREATMENT OR PREVENTION OF OPHTHALMIC PATHOLOGICAL CONDITIONS
EA201791333A1 (en) GLUCAGON DERIVATIVES WITH IMPROVED STABILITY
EA201791199A1 (en) METHOD OF TREATMENT OF ALZHEIMER'S DISEASE
EA202190569A1 (en) METHODS FOR TREATMENT OF FABRY DISEASE IN PATIENTS WITH GLA MUTATION
EA201300131A1 (en) COMBINED PHARMACEUTICAL COMPOSITION AND METHODS FOR THE TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH RESPIRATORY DISEASES OR CONDITIONS
EA202191175A1 (en) CYSTEINE-DESIGNED ANTIBODY-DRUG CONJUGATES CONTAINING PEPTIDE-CONTAINING LINKERS
EA201300421A1 (en) COMBINED THERAPY FOR THE TREATMENT OF HCV INFECTION
EA201892265A1 (en) METHODS OF TREATMENT OF OPHTHALMIC DISEASES
EA202090242A1 (en) TREATMENT OF FABRY DISEASE IN FZT-NAIVE AND FZT-TREATED PATIENTS
EA201992272A1 (en) Acylated Insulin Compound
NI201700024A (en) ANAMORELIN-BASED MEDICAL TREATMENTS
EA201691656A2 (en) THERAPEUTIC WAYS WITH THE USE OF NORIBOGOGINE AND RELATED COMPOUNDS
EA202190057A1 (en) SOLUBILIZED APIRAZES, METHODS AND APPLICATION
EA202190398A1 (en) CONDENSED RING DERIVATIVE USED AS FGFR4 INHIBITOR
EA202091112A1 (en) SOCRYSTALS, PHARMACEUTICAL COMPOSITIONS BASED ON THEIR BASED AND METHODS OF TREATMENT FOR THEIR APPLICATION
EA201591123A1 (en) THE COMBINATION OF THE AGONIST GLP1R AND METHFORMIN AND WAYS OF THEIR APPLICATION IN THE TREATMENT OF TYPE 2 DIABETES AND OTHER DISORDERS
PE20210123A1 (en) METHYLLACTAM RING COMPOUND AND PHARMACEUTICAL USE OF THE SAME
EA202090164A1 (en) Isotretinoin oral-mucous compositions and methods for their use
EA202191758A1 (en) PEPTIDES FOR THE TREATMENT AND PREVENTION OF DIABETES AND RELATED DISEASES
EA202191165A1 (en) ELACESTRANT IN COMBINATION WITH ABEMACYCLIBUS IN WOMEN WITH BREAST CANCER
EA201890497A3 (en) METHOD OF TREATMENT OF LABEL AND PAROXISMAL HYPERTENSION
EA202091653A1 (en) MINOCYCLINE FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES
EA202092045A1 (en) TREATMENT AND PREVENTION OF PREECLAMPSIA
EA201990550A1 (en) OPHTHALMIC DRUG INCLUDING THE ASOLIC COMPOUND

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU